BioSpace News Archive

Lipocine Inc. today announced that the Company will present at the H.C. Wainwright 5th Annual NASH Investor Conference being held virtually on October 12, 2021 .

GC Aesthetics®, Inc. (GCA), a privately-held medical technology company providing aesthetic solutions for global healthcare markets, announces successful surgical and patient care results in its multi-centric safety and efficacy study for nipple reconstruction using the novel silicone implant, FixNip NRI™.

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.

Amyris, Inc., a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, announced that Amyris has licensed the Onyx genome engineering platform from Inscripta, a leading gene editing technology company.

AtriCure, Inc. today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021.

Proscia ® , a leading provider of digital and computational pathology solutions, has released study results on new technology that leverages artificial intelligence (AI) to automatically detect melanoma, the deadliest form of skin cancer, with a high degree of accuracy.

Renexxion Ireland Ltd., a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need gastrointestinal disorders, announced that it has entered into a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH to jointly develop and commercialize Naronapride, a unique late-stage GI prokinetic, initially for gastroparesis.

Diamond Therapeutics Inc. is pleased to announce the appointment of Dr. Torsten Passie to its scientific advisory board.

Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it has entered into a transaction agreement to reach a definitive agreement by the end of November 2021 to acquire a subsidiary (“AiPharma”) of AiPharma Global Holdings LLC.